Literature DB >> 7515293

Vascular endothelial growth factor and its receptors.

G Neufeld, S Tessler, H Gitay-Goren, T Cohen, B Z Levi.   

Abstract

Vascular endothelial growth factor (VEGF) is a highly specific mitogen for vascular endothelial cells and an angiogenic factor that is structurally related to platelet derived growth factor (PDGF). It is also known as the vascular permeability factor (VPF) because it efficiently potentiates the permeabilization of blood vessels. Five types of VEGF mRNA encoding VEGF species which differ in their molecular mass and in their biological properties are transcribed from a single gene as a result of alternative splicing. VEGFs are produced and secreted by several normal cell types including smooth muscle, luteal and adrenal cortex cells. VEGFs are also produced by different tumorigenic cells, and appear to play a major role in tumour angiogenesis. Antibodies directed against VEGF can inhibit the growth of a variety of VEGF producing tumours. Of the various VEGF species, the best characterized is the 165 amino acid long form (VEGF165). VEGF165 is a heparin binding growth factor, and its interaction with VEGF receptors on the cell surface of vascular endothelial cells depends on the presence of heparin-like molecules. Several cell types which do not proliferate in response to VEGF such as bovine corneal endothelial cells, HeLa cells and human melanoma cells also express cell surface VEGF receptors, but the function of the VEGF receptors in these cells is unclear. Recently, the tyrosine-kinase receptors encoded by the flt and KDR/flk-1 genes were found to function as VEGF165 receptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7515293     DOI: 10.1016/0955-2235(94)90019-1

Source DB:  PubMed          Journal:  Prog Growth Factor Res        ISSN: 0955-2235


  41 in total

1.  Contradictory Concepts in the Etiology and Regression of Kaposi's Sarcoma. The Ferenc Györkey Memorial Lecture.

Authors:  Joseph G Sinkovics
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

Review 2.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

3.  Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site.

Authors:  Y A Muller; B Li; H W Christinger; J A Wells; B C Cunningham; A M de Vos
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

4.  Enhanced endothelialization on surface modified poly(L-lactic acid) substrates.

Authors:  Hao Xu; Rajendrasing Deshmukh; Richard Timmons; Kytai Truong Nguyen
Journal:  Tissue Eng Part A       Date:  2010-12-18       Impact factor: 3.845

5.  Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor.

Authors:  Marcella Marcellini; Naomi De Luca; Teresa Riccioni; Alessandro Ciucci; Angela Orecchia; Pedro Miguel Lacal; Federica Ruffini; Maurizio Pesce; Francesca Cianfarani; Giovanna Zambruno; Augusto Orlandi; Cristina Maria Failla
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

6.  Neoplastic transformation and angiogenesis in the thymus of transgenic mice expressing SV40 T and t antigen under an L-pyruvate kinase promoter (SV12 mice).

Authors:  Bernadette Nabarra; Christiane Pontoux; Cecile Godard; Mary Osborne-Pellegrin; Sophie Ezine
Journal:  Int J Exp Pathol       Date:  2005-12       Impact factor: 1.925

Review 7.  Astrocytic response to cerebral ischemia is influenced by sex differences and impaired by aging.

Authors:  Nioka C Chisholm; Farida Sohrabji
Journal:  Neurobiol Dis       Date:  2015-04-02       Impact factor: 5.996

Review 8.  Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants.

Authors:  G Neufeld; T Cohen; H Gitay-Goren; Z Poltorak; S Tessler; R Sharon; S Gengrinovitch; B Z Levi
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

9.  Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients.

Authors:  Galatea Kallergi; Harris Markomanolaki; Vicky Giannoukaraki; Maria A Papadaki; Areti Strati; Evi S Lianidou; Vassilis Georgoulias; Dimitris Mavroudis; Sofia Agelaki
Journal:  Breast Cancer Res       Date:  2009-11-17       Impact factor: 6.466

10.  A novel fragment derived from the beta chain of human fibrinogen, beta43-63, is a potent inhibitor of activated endothelial cells in vitro and in vivo.

Authors:  E Krajewska; C E Lewis; Y-Y Chen; A Welford; S Tazzyman; C A Staton
Journal:  Br J Cancer       Date:  2010-01-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.